Brain

Cresilon’s Revolutionary Hemostatic Gel Technology Shows Promising Results for Treatment of Penetrating Traumatic Brain Injury in Study Performed with Walter Reed Army Institute of Research

Findings from preclinical study demonstrate potential for a field and prehospital treatment following a penetrating TBI NEW YORK, July 9,…

6 months ago

Hop on a Cure Makes Financial Contribution Toward ALS CURE Project

ATLANTA, GA / ACCESSWIRE / July 9, 2024 / Hop On A Cure, a leading advocate in the fight against…

6 months ago

Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial

Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company’s Pivotal Human Clinical…

6 months ago

American Shared Hospital Services Announces Signing of Joint Venture Agreement for Gamma Knife Facility in Guadalajara, Mexico

JV will Establish Company’s 4th International CenterSAN FRANCISCO, July 09, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS)…

6 months ago

Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024

SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical…

6 months ago

Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team

MALVERN, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),…

6 months ago

Seyltx Announces Results of Electronic Health Record Analysis to Determine the Prevalence of Refractory Chronic Cough

- Data will be presented at the London International Cough Symposium on July 18, 2024 - 54,958,289 adult patients in…

6 months ago

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of…

6 months ago

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August…

6 months ago

STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors

Sarma1 2 Dr. Purnanand Sarma, PhD Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and…

6 months ago